Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2023-11-07 Foreign Filer Report
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-11-07 English
Inside Information / Other news releases
Call Transcript Classification · 1% confidence The document is titled "INNATE PHARMA ANNOUNCES CONFERENCE CALL FOR THIRD QUARTER 2023 BUSINESS UPDATE". It explicitly states the purpose is to announce a conference call to discuss business progress during the third quarter of 2023, providing the date, time, and access links for the event. This content perfectly matches the definition of a Call Transcript (CT) if it were the transcript itself, or an Earnings Release (ER) if it were the results. However, since this document is an *announcement* of a future conference call, it is not the transcript (CT) nor the actual earnings release (ER). It is an announcement related to the reporting of results, which often accompanies an ER or IR. Given the options, the closest fit for an announcement detailing an upcoming call to discuss quarterly performance is often categorized alongside Earnings Releases (ER) or, if it's purely logistical, sometimes as a Regulatory Filing (RNS). Since the core purpose is to schedule a call to discuss quarterly updates, it is most closely related to the earnings cycle. However, the document itself is an announcement of a *future* call, not the release of the results or the transcript of the call itself. If the document were the actual transcript, it would be 'CT'. If it were the financial highlights, it would be 'ER'. Since it is an announcement *about* the call, and it is not a general regulatory filing, the most appropriate category among the specific options that deals with scheduled calls/updates is often grouped with 'CT' or 'ER'. Given the options, and recognizing this is a pre-event announcement, it is best classified as a Call Transcript (CT) if we interpret this as the material *leading* to the call, or if we strictly follow the definitions, it is an announcement about an event. Since 'CT' is defined as the 'Full text transcript of company conference calls', and this is an announcement *of* the call, it doesn't fit perfectly. However, in many databases, announcements of earnings calls are grouped with the earnings cycle documents. Let's re-evaluate: It announces a call to give a 'business update'. This is highly related to earnings. It is not a 10-K, AR, or IR. It is not a DIV, CAP, or SHA. It is not a DIRS or MANG. It is an announcement of a future event. If the document were short and just said 'Report attached', it would be RPA. This document is substantial and details the event. Since it is announcing the mechanism for discussing quarterly results, and 'CT' is the closest category related to conference calls, I will select 'CT' as the most relevant category for a call announcement, although 'ER' is also plausible if the call is primarily for earnings. Given the focus on the *call* itself, CT is the best fit among the specific options.
2023-11-07 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is titled 'INNATE PHARMA ORGANISE UNE CONFÉRENCE TÉLÉPHONIQUE POUR SES RÉSULTATS FINANCIERS AU TROISIÈME TRIMESTRE 2023' (Innate Pharma organizes a conference call for its third-quarter 2023 financial results). It explicitly announces a conference call and webcast scheduled for November 14, 2023, to discuss the Q3 2023 financial results. This structure—announcing a call to discuss period results—is the defining characteristic of an Earnings Release (ER) or, more specifically, the announcement leading up to the detailed discussion, which often overlaps with the Earnings Release content or precedes the full Call Transcript (CT). Since the text focuses entirely on scheduling the call to present the results and includes executive names, it functions as the primary announcement of the earnings event. If the text contained the full transcript, it would be CT. If it were the comprehensive financial report, it would be IR. As it is the announcement of the call to discuss the results, it aligns best with the Earnings Release (ER) category, which covers the initial announcement of periodical financial results (key highlights often precede or accompany this call announcement). 9M 2023
2023-11-07 French
INNATE PHARMA S.A. 6-K
Foreign Filer Report
2023-11-03 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated November 3, 2023, announcing that Innate Pharma has new clinical data for its drug candidates (lacutamab and SAR443579/IPH6101) selected for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in December 2023. It details the specific abstracts, presentation types (oral presentation, poster session), publication numbers, and session times. This is not a full financial report (10-K, IR), an earnings release (ER), or a formal proxy/governance document. It is an announcement about scientific data being presented at a conference. While it contains some financial context (forward-looking statements, stock info), its primary purpose is to disseminate clinical trial updates and presentation schedules. This type of announcement, which is a general corporate update regarding scientific progress and upcoming disclosures, fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate communication, or potentially an Investor Presentation (IP) if it were the presentation itself, but since it's an announcement *about* presentations, RNS is the most appropriate fallback for a non-standard filing type.
2023-11-03 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated November 3, 2023, announcing that Innate Pharma's abstracts, including an oral presentation, have been selected for presentation at the 65th annual meeting of the American Society of Hematology (ASH) 2023. It details the clinical data for lacutamab and SAR443579/IPH6101 that will be presented at the conference. This is not a full financial report (10-K or IR), nor is it a formal regulatory filing like a DEF 14A or a DVA. It is an announcement about upcoming scientific/clinical data presentations at a major industry conference. This type of announcement, which details scientific progress and upcoming presentations, is best classified as an Investor Presentation (IP) or, given the context of announcing specific data to be presented at a conference, it strongly aligns with the purpose of informing investors about clinical pipeline updates, which often accompanies or precedes a formal Investor Presentation. However, since the core content is the announcement of data being presented at a scientific meeting, and it is a press release format, it is most closely related to the information shared in an Investor Presentation (IP) or a general Regulatory Filing (RNS). Given the detailed nature of the clinical data summaries provided, it functions as a preview of investor-facing material. If the document were solely announcing the *publication* of a report, RPA would be chosen. Since it details the content of the upcoming scientific presentations, IP is a strong fit, but RNS is the safest fallback for non-standard announcements. Considering the focus on clinical trial results and pipeline updates, which are key components of investor relations materials, I will lean towards IP, as it is more specific than RNS for this content type, although it is an announcement *about* presentations rather than the presentation itself. Given the options, and recognizing this is a press release detailing scientific milestones, it is a form of investor communication. If the document were the actual presentation slides, IP would be certain. As a press release detailing the content of presentations, it serves a similar informational purpose. I will classify it as an Investor Presentation (IP) because the substance is clinical data updates intended for investors, even if delivered via a press release format detailing conference abstracts.
2023-11-03 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.